NCT04387110View on ClinicalTrials.gov

Ocrelizumab in Breastmilk

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
Multiple SclerosisClinically Isolated Syndrome
Interventions
DRUG

Ocrelizumab

Receiving either 1infusion (600mg) or 2 infusions (300mg).

Trial Locations (1)

94158

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER